Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aventis Arava Liver Toxicity Warning Is Satisfactory, FDA Arthritis Cmte. Says

Executive Summary

Aventis' existing labeled warnings for Arava regarding liver toxicity do not need to be strenghened, members of FDA's Arthritis Advisory Committee told the agency at its March 5 safety review of the arthritis drug

You may also be interested in...



FDA Looked To Arava’s Safety Experience In Gauging Aubagio’s Risks

Agency’s assessment of teriflunomide for multiple sclerosis incorporated the known safety data for leflunomide, a chemically related drug with an extensive post-marketing record in rheumatoid arthritis. Despite hepatotoxicity and other safety concerns with the older drug, its clinical experience provided reassurance that Aubagio’s risks could be managed without a REMS.

CDER Dispute Resolution Policy Will Test “Ad Hoc” Arbitration

FDA's Center for Drug Evaluation & Research will run a one-year test of a formal dispute resolution process to resolve differences of opinion among reviewers

CDER Dispute Resolution Policy Will Test “Ad Hoc” Arbitration

FDA's Center for Drug Evaluation & Research will run a one-year test of a formal dispute resolution process to resolve differences of opinion among reviewers

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS041380

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel